In a landmark moment for India's space ambitions, Indian astronaut Shubhanshu Shukla has blasted off to the International Space Station (ISS) as part of the Axiom-4 mission , marking the country's return to human spaceflight after a 41-year hiatus . This historic launch from NASA’s Kennedy Space Center in Florida has not only reignited national pride but also officially kickstarted India’s human spaceflight programme . The mission, operated by Axiom Space , includes a four-member international crew that will spend 14 days in orbit , conducting scientific research, outreach programs, and various commercial activities. This momentous occasion places India among a select group of nations capable of sending humans into space and reflects the growing prowess of the Indian space sector . A New Chapter: Shubhanshu Shukla and India’s Astronautical Comeback The last Indian to go to space was Rakesh Sharma in 1984, aboard the Soviet spacecraft Soyuz T-11. Now, in 2025, Shubhanshu...
The global biosimilar market is expanding rapidly, with pharmaceutical companies forging strategic alliances to enhance their reach and market share. In a significant development, Dr. Reddy’s Laboratories and China’s Bio-Thera Solutions have signed an agreement to introduce two biosimilars in the Southeast Asian market . This partnership reflects the growing demand for affordable biologic alternatives and strengthens both companies' presence in the global biopharmaceutical landscape . Why This Deal Matters With the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, the demand for biosimilars is soaring. Biologic drugs , while highly effective, are often expensive, creating accessibility challenges in emerging markets like Southeast Asia. This collaboration between Dr. Reddy’s and Bio-Thera aims to bridge this gap by offering cost-effective, high-quality biosimilars . Key Highlights of the Agreement 1. Focus on Two Biosimilar Products Th...